Albemarle Optimizes Smallpox Drug Candidat... ( Fine Chemistry Services unit demonstr...)

Albemarle Optimizes Smallpox Drug Candidate for SIGA

Date:5/5/2008

Fine Chemistry Services unit demonstrates pilot production for "fast track"

drug

BATON ROUGE, La., May 5 /PRNewswire-FirstCall/ -- Two American companies are teaming up for second-round test-phase production of a FDA-designated "fast track" drug candidate to treat smallpox, a deadly virus that is feared to be able to reach people through acts of bio-warfare or bio-terrorism.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO )

Albemarle Corporation (NYSE: ALB), a leading global provider of custom pharmaceutical manufacturing services, was selected by SIGA Technologies (Nasdaq: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, to provide scale-up and manufacturing services for ST-246, SIGA's leading smallpox antiviral candidate.

Caused by the variola virus, smallpox is no longer found generally in the environment, but it is considered a formidable bio-warfare threat. SIGA's ST-246 has shown evidence of safety and high levels of efficacy against poxvirus disease in multiple animal trials, as well as continued success in human safety studies.

As a result of success in early trials and in one emergency compassionate use case, the FDA has designated ST-246 for "fast track" status. Activities supporting a New Drug Application (NDA) are currently in process.

Under its existing manufacturing agree
'/>"/>

SOURCE Albemarle Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND

Post Your Comments:

(Date:11/19/2008)...d not achieve statistical significance , , ...harmos Corporation (Nasdaq: PARS ) today announc... topical NanoEmulsion (NE) drug delivery technolog... , The multi-center, randomized, double-blin... and efficacy of the Company,s 3% Diclofenac Dieth...

(Date:11/19/2008)...Nov. 19 Biotech scientists increas...logy research to better understand the effects of ...s, reports Genetic Engineering & Biotechnolog... figuring out a new compound,s mechanism of action... technique, according to the November 15 issue of ...

(Date:11/19/2008)... Payment from Roche- , , MONTVALE, N.J., No...cals Corp. (Nasdaq: MEMY ) today announced that ...2 trial of R3487/MEM 3454, its lead alpha-7 nicoti...ciated with schizophrenia (CIAS). The Company has...ggering a $5.0 million payment from its partner Ro...

(Date:11/18/2008)...seals.org to learn more, make a donation or send ...v. 17 Millions will rec...esy of the American Lung Association. These decora...ing tradition dating back to 1907 when the Lung As..., , "Most Americans alive today have no vivi...

[0] Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream [0] GEN Reports on the Trend Toward Predictive Toxicogenomics [0] Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia [0] American Lung Association Celebrates 101st Annual Christmas Seals Campaign

...7 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. tod...from a,Phase 1b clinical trial with atacicept in B...American Society of Clinical,Oncology (ASCO) 2007 ...inistration of higher doses than had been tested i... well-tolerated and biologically,active at all dos...

... WIRE)--Jun 4, 2007 - Cougar Biotechnology,Inc. (... Phase I,and Phase II data on the Company,s prosta...te) was presented at the American Society,of Clini...ntly,taking place in Chicago, Illinois. The data w...ay, June 2nd, as part of the poster,discussion ses...

Other Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2 ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 2 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 3 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 4 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 5 Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 6

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting

(Date:11/21/2008).../ -- The Generic,Pharmaceutical Association (GPhA...A President and CEO Kathleen Jaeger regarding the ...rging Health Care Competition and Consumer Issues....ng this roundtable demonstrates the,growing momen...safe and,affordable biogenerics sooner rather tha...

(Date:11/21/2008)...e University of Texas M. D. Anderson Cancer Cent...to eradicate breast cancer in Panama through the P...h of the Americas today at an event with Laura Bus... Fernandez de Torrijos, the First Lady of Panama. ...e are the U.S. Department of State and Susan G. Ko...

(Date:11/21/2008).../ -- U.S. News & World Report and the National...eChoice(R) HealthPlan of South Carolina in the top...ed in U.S. News & World Report,s issue this we...the nation,s best health plans based on clinical q... scores. NCQA and U.S. News & World Report ran...

(Date:11/21/2008)...ic damage that can lead to disease , , F...ications for treating attention-deficit hyperactiv...nked to an increased risk for developing cancer, a...rs at Duke University Medical Center and the Natio...that reported biomarkers associated with an increa...

Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2 Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2 Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3 Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2 Health News:ADHD Medications Don't Pose Cancer Risk 2

[0] GPhA Statement on FTC Roundtable on Biogenerics [0] First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama [0] BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans [0] ADHD Medications Don't Pose Cancer Risk

...-Sinai Medical Center this week launched an Intern...duct both adult and embryonic stem cell research. ...arrival of renowned Israeli developmental genetici...the institute’s co-director along with David I. Me...

... temperatures have been on an all time high in the...keeping tabs on the rising temperature and polluti...during the period from 15th to 19th July, the temp...ong with nitrogen dioxide pollution, which is know...

...nt investigation reveals that vocal cord dysfuncti... M. Weinberger, of the University of Iowa,// and h...s who were reported to be suffering from this dysf...patients, 41 were reported to be suffering from as...

... 40 percent of female German smokers refuse to qui...tive study by the Instituts Gewis for the Hamburg-...ed, 39 percent of those between ages 25 and 39 rep...n weight." Experts disagree. Most smokers do gain...

Other Medicine News:Health News:Center Launches New International Stem Cell Research Institute 2 Health News:Sensor Images Show Soaring Temperature and Pollution Levels in UK 2

Center Launches New International Stem Cell Research Institute Sensor Images Show Soaring Temperature and Pollution Levels in UK Dysfunction of Vocal Cord Often Misdiagnosed for Asthma Women Smokers Fear Quitting Will Lead to Weight Gain

...ple, effective screening test which is used to ide...d sugar) levels which are often a warning sign of ...h requires a single drop of blood obtained from a ...n in clinical trials to be 94 to 99.95 percent acc...

The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program.

CardioChek™ PA Portable Whole Blood Test System

The Accustrip Strep A(ll) Test is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid

Medicine Products:

Chemcard Glucose Test Lifestream Plus Cholesterol Monitor CardioChek™ PA ACCUSTRIP Strep A (ll) Test-CLIA waived

Albemarle Optimizes Smallpox Drug Candidat...( Fine Chemistry Services unit demonstr...),Health